The ACME Laboratories Statistics
Total Valuation
DSE:ACMELAB has a market cap or net worth of BDT 16.12 billion. The enterprise value is 36.54 billion.
| Market Cap | 16.12B |
| Enterprise Value | 36.54B |
Important Dates
The last earnings date was Wednesday, January 28, 2026.
| Earnings Date | Jan 28, 2026 |
| Ex-Dividend Date | Nov 19, 2025 |
Share Statistics
DSE:ACMELAB has 211.60 million shares outstanding.
| Current Share Class | 211.60M |
| Shares Outstanding | 211.60M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.01% |
| Owned by Insiders (%) | 38.45% |
| Owned by Institutions (%) | 7.51% |
| Float | 130.25M |
Valuation Ratios
The trailing PE ratio is 6.29.
| PE Ratio | 6.29 |
| Forward PE | n/a |
| PS Ratio | 0.41 |
| PB Ratio | 0.59 |
| P/TBV Ratio | 0.59 |
| P/FCF Ratio | 9.55 |
| P/OCF Ratio | 3.74 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.09, with an EV/FCF ratio of 21.64.
| EV / Earnings | 14.26 |
| EV / Sales | 0.94 |
| EV / EBITDA | 4.09 |
| EV / EBIT | 5.36 |
| EV / FCF | 21.64 |
Financial Position
The company has a current ratio of 1.17, with a Debt / Equity ratio of 0.90.
| Current Ratio | 1.17 |
| Quick Ratio | 0.35 |
| Debt / Equity | 0.90 |
| Debt / EBITDA | 2.75 |
| Debt / FCF | 14.59 |
| Interest Coverage | 2.09 |
Financial Efficiency
Return on equity (ROE) is 9.72% and return on invested capital (ROIC) is 10.04%.
| Return on Equity (ROE) | 9.72% |
| Return on Assets (ROA) | 7.22% |
| Return on Invested Capital (ROIC) | 10.04% |
| Return on Capital Employed (ROCE) | 18.38% |
| Weighted Average Cost of Capital (WACC) | 7.38% |
| Revenue Per Employee | 4.31M |
| Profits Per Employee | 283,982 |
| Employee Count | 9,025 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 1.81 |
Taxes
In the past 12 months, DSE:ACMELAB has paid 1.05 billion in taxes.
| Income Tax | 1.05B |
| Effective Tax Rate | 29.01% |
Stock Price Statistics
The stock price has increased by +1.33% in the last 52 weeks. The beta is 0.01, so DSE:ACMELAB's price volatility has been lower than the market average.
| Beta (5Y) | 0.01 |
| 52-Week Price Change | +1.33% |
| 50-Day Moving Average | 72.31 |
| 200-Day Moving Average | 74.78 |
| Relative Strength Index (RSI) | 68.08 |
| Average Volume (20 Days) | 165,707 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, DSE:ACMELAB had revenue of BDT 38.86 billion and earned 2.56 billion in profits. Earnings per share was 12.11.
| Revenue | 38.86B |
| Gross Profit | 16.32B |
| Operating Income | 6.82B |
| Pretax Income | 3.61B |
| Net Income | 2.56B |
| EBITDA | 8.91B |
| EBIT | 6.82B |
| Earnings Per Share (EPS) | 12.11 |
Balance Sheet
The company has 4.21 billion in cash and 24.63 billion in debt, with a net cash position of -20.42 billion or -96.49 per share.
| Cash & Cash Equivalents | 4.21B |
| Total Debt | 24.63B |
| Net Cash | -20.42B |
| Net Cash Per Share | -96.49 |
| Equity (Book Value) | 27.29B |
| Book Value Per Share | 128.97 |
| Working Capital | 3.97B |
Cash Flow
In the last 12 months, operating cash flow was 4.31 billion and capital expenditures -2.62 billion, giving a free cash flow of 1.69 billion.
| Operating Cash Flow | 4.31B |
| Capital Expenditures | -2.62B |
| Free Cash Flow | 1.69B |
| FCF Per Share | 7.98 |
Margins
Gross margin is 42.01%, with operating and profit margins of 17.56% and 6.60%.
| Gross Margin | 42.01% |
| Operating Margin | 17.56% |
| Pretax Margin | 9.29% |
| Profit Margin | 6.60% |
| EBITDA Margin | 22.93% |
| EBIT Margin | 17.56% |
| FCF Margin | 4.34% |
Dividends & Yields
This stock pays an annual dividend of 3.50, which amounts to a dividend yield of 4.59%.
| Dividend Per Share | 3.50 |
| Dividend Yield | 4.59% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 28.90% |
| Buyback Yield | n/a |
| Shareholder Yield | 4.59% |
| Earnings Yield | 15.90% |
| FCF Yield | 10.47% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
DSE:ACMELAB has an Altman Z-Score of 1.74 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.74 |
| Piotroski F-Score | 7 |